• 1
    Longstreth GS, Olde-Tsadik G. irritable bowel-type symptoms in HMO examinees. Dig Dis Sci 1993; 38: 15819.
  • 2
    Jones R, Lydiard S. Irritable bowel syndrome in the general population. BMJ 1992; 304: 8790.
  • 3
    Silk DBA. Impact of irritable bowel syndrome on personal relationships and working practices. Eur J Gastroenterology &Hepatology 2001; 13: 132732.
  • 4
    Jones J, Boorman J, Cann P, et al. British Society of Gastroenterology guidelines for the management of irritable bowel syndrome. Gut 2000; 47(suppl 11): 19.
  • 5
    Wells NEJ, Halin BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 101930.
  • 6
    Horwitz BJ, Fisher RS. The irritable bowel syndrome. N Engl J Med 2001; 334: 184650.
  • 7
    Silk DBA. Management of irritable bowel syndrome: start of a new era? Eur J Gastroenterology & Hepatology 2003; 15: 67996.
  • 8
    Longstreth GF, Grant-Thompson W, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 148091.
  • 9
    Shanahan F. Therapeutic manipulation in gut flora. Science 2000; 289: 1211312.
  • 10
    Collins SM. The immuno modulation of enteric neuromuscular functions. Implication for motility and inflammatory disorders. Gastroenterology 1996; 111: 168399.
  • 11
    Garcia-Rodrigues LA, Ruigomes A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999; 318: 5656.
  • 12
    Gwee KA, Graham JC, McKendric MW, et al. Psychometric scores and persistence of irritable bowel syndrome after infectious diarrhoea. Lancet 1996; 347: 1503.
  • 13
    Neal KR, Hebden J, Spiller RC. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMI 1997; 314: 77982.
  • 14
    Gwee KA, Leong YL, Graham C, et al. The role of psychological and biological factors in post infective gut dysfunction. Gut 1999; 44: 4006.
  • 15
    Spiller RC, Jenkins D, Thornely JP, et al. Increased rectal mucosal enteroendocrine cells. Lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 80411.
  • 16
    Chadwick V, Chen W, Shin D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 177883.
  • 17
    King TS, Elia M, Hunter J. Evidence for abnormal fermentation in irritable bowel syndrome. Lancet 1998; 352: 11879.
  • 18
    Di-Stefano M, Strocchi A, Malservisc S, Veneto G, Ferrieri A, Corazza GR. Non-absorbable antibiotics for managing intestinal gas production and gas related symptoms. Aliment Pharmacol Ther 2000; 14: 10018.
  • 19
    O’Leary C, Quigley EMM. Small bowel bacterial overgrowth, celiac disease and IBS. What are the associations?. What are the associations? Am J Gastroenterol 2003; 98: 7202.
    Direct Link:
  • 20
    Gorbech SL. Probiotics in the third millennium. Dig Liver Dis 2002; 34(Suppl 2): S27.
  • 21
    O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 54151.
  • 22
    Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterolol 2006; 101: 158190.
    Direct Link:
  • 23
    Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2008; 26: 47586.
  • 24
    Gibson GR, Roberfroid MB. Dietary modulataion of the human colonic microflora introducing the concept of prebiotics. J Nutr 1995; 125: 140112.
  • 25
    Depeint F, Tzortzis G, Vulevic J, L’anson K, Gibson Gr. Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 44171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study. Am J Clin Nutr 2008; 87: 78591.
  • 26
    Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45: 11437.
  • 27
    Heaton KW, O’Donnell LJ. An office guide to whole-gut transit time. Patients recollection of their stool form. J Clin Gastroenterol 1994; 19: 2830.
  • 28
    Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of trials for functional gastrointestinal disorders. Gut 1999; 45: 116877.
  • 29
    Rycroft CE, Jones MR, Gibson GR, Rastall RA. A comparative in vitro evaluation of the fermentation properties of prebiotic oligosaccharides. J Appl Microbio 2001; 91: 87887.
  • 30
    Langendijk PS, Schut F, Jansen GJ, et al. Quantitative fluorescent in situ hybridization of bifidobacterium spp. with genus-specific 16S rRNA-targeted probes and its application in faecal samples. Appl Environ Microbiol 1995; 61: 306975.
  • 31
    Franks AH, Harmsen HJM, Raangs GC, Jansen GJ, Shut F, Welling GW. Variations of bacterial populations in human faeces measured by fluorescent in situ hybridization with group specific 16S rRNA-targeted oligonucleotide probes. Appl Environ Microbiol 1998; 64: 333645.
  • 32
    Manz W, Amann R, Ludwig W, Vananneyt M, Schleifer KH. Application of a suite of 16S rRNA-specific oligonucleotide probes designed to investigate bacteria of the phylum cytophagaflavobacter-bacteroides in the natural environment. Microbiology 1996; 142: 1097106.
  • 33
    Harmsen HJM, Elfferich P, Shut F, Welling GW. A 16S rRNA-targeted probe for detection of lactobacilli and enterococci in faecal samples by fluorescent in situ hybridization. Microb Ecol Health D 1999; 11: 312.
  • 34
    Poulsen LK, Lan F, Kristensen CS, Hobolth P, Molin S, Krogfelt KA. Spatial distribution of Escherichia coli in the mouse large intestine inferred from RRNA in situ hybridization. Infect Immun 1994; 62: 51914.
  • 35
    Devereux R, Kane MD, Winfrey J, Stahl DA. Genus- and group-specific hybridisation probes for determinative and environmental studies of sulphate-reducing bacteria. Syst Appl Microbiol 1992; 15: 6019.
  • 36
    Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-!OL: a disease-specific quality of life questionnaire. Am J Gastroenterol 2000; 95: 9991007.
    Direct Link:
  • 37
    Zigmoid AS, Snaity RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 36170.
  • 38
    Foods Standard Agency (2002) McCance and Widdowson’s The Composition of Foods. Sixth Summary Edition. Cambridge: Royal Society of Chemistry.
  • 39
    Mitsuoka T, Kanemochi C. Importance of Bifidobacterium in GUT health. Amer J Clin Nutri 1977; 30: 1799810.
  • 40
    Vos AP, M’Rabert L, Stahl B, Boehm G, Garssen J. Immunomodulatory effects and potential working mechanisms of orally applied nondigestible carbohydrates. Crit Rev Immunol 2007; 27: 97140.
  • 41
    Bradley HK, Wyatt GM, Bayliss CE, Hunter JO. Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol 1987; 23: 2932.
  • 42
    Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982; 5: 18594.
  • 43
    Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001; 152: 73541.
  • 44
    Parkes GC, Rayment NB, Hudspith BN, et al. Dysbiosis in diarrhoea predominant irritable bowel syndrome: significant increase in mucosa-associated bacteroides. Gut 2008; 57(suppl 1): A157.
  • 45
    Biarati B, Matterelli P. The family Bifidobacteria. In: DworkinM, FalkowS, RosenbergE, SchieiferKH, StackebrandtE, eds. The Prokaryotes. New Yors: Springer, 2001: 170.
  • 46
    Spiller R. Probiotics: an ideal anti-inflammatory treatment for IBS? Gastroenterology 2005; 128: 7835.